Cell Therapy Lot Release Specifications — Acceptance Criteria That Protect Patients and Enable Manufacturing

The specifications for a cell therapy lot are the single document that determines what goes into a patient. In personalized medicine manufacturing, they also determine whether you can treat the patient at all.

For autologous cell therapy programs — particularly dendritic cell vaccines and CAR-T products — the lot release specification is not simply a quality document. It is a manufacturing constraint that sets the boundary between a product that ships and a patient who receives treatment. When specifications are designed without explicit justification, without a rapid-testing strategy for compressed autologous timelines, or without numerical acceptance criteria grounded in manufacturing capability data, the consequences arrive simultaneously at two points: the pre-BLA meeting and the clinic. Setting justified specifications for cell therapy products — balancing patient safety, manufacturing capability, and the limited early-phase data available to support numerical acceptance criteria — requires a specification philosophy and an architecture that most cell therapy CMC teams have not fully developed.

The Lot Release Specification Architecture for Cell Therapy: The Minimum Required Package for CBER

CBER’s minimum required lot release package for a cell therapy product is anchored in ICH Q6B — issued domestically as FDA’s guidance, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products — which requires that acceptance criteria be scientifically justified and that the selected test procedures be suitable for their intended purpose. For cell therapy products, this translates to a specification table that addresses identity, purity, viability, potency, sterility, mycoplasma, and endotoxin — each with a defined method, a numerical acceptance criterion, and a documented rationale that traces the criterion to either historical manufacturing data, clinical safety data, or explicit regulatory precedent. The absence of any one of these elements is not a formatting error; it is a substantive deficiency that draws a CBER review comment and, in some cases, a clinical hold.

What distinguishes a cell therapy specification package from a conventional biologics specification is the requirement to account for both product-specific biology and patient-specific logistics. For a monocyte-derived dendritic cell (moDC) therapy, where the manufacturing process runs from leukapheresis through CD14+ monocyte selection (targeting ≥90% purity by CliniMACS CD14 MicroBead Kit), through immature DC generation with GM-CSF at 500–1,000 ng/mL and IL-4 at 500–1,000 ng/mL, and through a maturation step that can employ the Jonuleit cytokine cocktail (TNF-α + IL-1β + IL-6 + PGE2) or LPS at 1 μg/mL plus IFN-γ at 500 IU/mL — the total manufacturing window may be 5–7 days for DC generation plus maturation. Lot release specifications must reflect what can actually be tested within that window. FDA’s CMC Information for Human Gene Therapy INDs (2020) reinforces that the testing strategy itself must be described and justified as part of the submission, not assumed to mirror conventional 14-day sterility methods.

For sipuleucel-T (Provenge, BLA 125197, approved 2010), the first FDA-approved antigen-presenting cell therapy, CBER accepted a lot release framework built around a compressed, approximately 3-day process from leukapheresis to patient infusion — including a 36- to 44-hour ex vivo antigen-loading/culture step and a product shelf life measured in hours after release — a manufacturing constraint that made conventional compendial testing architectures unworkable. The regulatory precedent is instructive: CBER will accept a rapid-testing strategy when the autologous manufacturing timeline is documented, the alternative method is validated, and the tradeoffs are transparently disclosed in the IND CMC section.

Viability, Identity, Purity, and Potency: The Four Core Cell Therapy Release Tests and Their Acceptance Criteria

Viability is among the most consequential cell therapy specifications and, paradoxically, among the most poorly designed in early-phase packages. CBER has issued deficiency comments on programs that set viability acceptance criteria at ≥50% — a threshold that reflects manufacturing convenience rather than patient safety and that lacks any published clinical basis to justify releasing a product at that floor. For dendritic cell therapies, a viability specification of ≥70% or higher is more defensible, and for mature DC products specifically, a specification below ≥70% raises questions about whether the DC population retains sufficient functional capacity to stimulate T cell responses in vivo. ICH Q6B’s principle that acceptance criteria should be set based on data from lots used in preclinical and clinical studies applies directly: if no clinical lots were manufactured below 75% viability, the acceptance criterion cannot be justified at 50% without prospective risk analysis.

Identity and purity specifications for dendritic cell therapies are defined at the level of surface phenotype and require quantitative marker expression thresholds. Mature DC specifications routinely include CD80 ≥60%, CD83 ≥60%, CD86 ≥60%, and HLA-DR ≥90%, with CCR7 ≥40% as a marker of migratory capacity — each assessed by flow cytometry. These thresholds are not arbitrary: CD83 expression is the most widely accepted marker of DC maturation status, and a specification that lists CD83 without a numerical lower limit — or that includes only CD14 negativity as an identity test — fails to demonstrate that the product population has achieved the functional state required for antigen presentation and T cell priming. CBER reviewers will flag identity specifications that are qualitative without quantitative anchors, because a “positive result” for CD83 expression with no threshold is untestable and unverifiable across lots.

Potency specifications for DC therapies present the most complex design challenge in the lot release package. USP <1046> states that potency tests for cell-based therapy products must be based on a relevant biological activity and must, at minimum, demonstrate that the product performs its intended function. For moDC products, the primary potency assay is typically a T cell stimulation assay — measuring autologous T cell proliferation by CFSE dilution or 3H-thymidine incorporation — or a functional maturation marker such as IL-12p70 secretion by ELISA, which reflects the DC’s capacity to drive Th1 polarization. FDA’s Potency Tests for Cellular and Gene Therapy Products (2011) guidance explicitly states that a potency specification consisting only of a “positive result” — without a quantitative lower limit — is insufficient for a Phase 2 or later IND, and is a common reason for CMC review comments requesting a revised potency strategy.

Sterility, Mycoplasma, and Endotoxin: The Safety Specifications That Cannot Be Compromised

Sterility and endotoxin specifications represent the non-negotiable safety floor of any cell therapy lot release package, but the testing strategy must be designed with the same manufacturing-specific thinking applied to identity and potency. For autologous DC therapies with compressed release timelines, the compendial 14-day sterility test (USP <71>) cannot return results before the product must be infused. CBER expects programs with release timelines under 72 hours to describe their rapid sterility testing strategy — typically a validated nucleic acid amplification test (NAT)-based method — in the IND CMC section, with validation data demonstrating equivalence to the compendial method. A specification that cites sterility testing without specifying the method, the timeline, and the regulatory basis for the alternative approach is one of the five most common deficiency patterns CBER flags in cell therapy CMC reviews.

Endotoxin specifications must be expressed per patient dose, not per milliliter of product, to align with the endotoxin limit calculation framework established by FDA’s Process Validation Guidance (2011) Stage 2 performance qualification criteria and with ICH Q6B’s requirement that acceptance criteria be clinically relevant. A common error is carrying forward an endotoxin limit of 5 EU/mL from an early-phase IND without converting to a dose-based limit — for a DC therapy infused as 5–10 mL of cell suspension, the total endotoxin load delivered to the patient may exceed the systemic endotoxin threshold for an immunocompromised oncology patient without the per-mL limit triggering a release failure.

Mycoplasma testing in cell therapy lots must appear in the release specification as a named test with an explicit acceptance criterion of “no growth detected” — not as an in-process control only. For manufacturing processes that use feeder-free, animal component-free media, the mycoplasma risk is reduced but not eliminated, and CBER expects mycoplasma to remain a lot release attribute through Phase 2. The failure mode here is not contamination itself — it is a specification package that lists mycoplasma as “tested per internal SOP” without defining the method, the compendial reference, or the accept/reject criterion in the CTD.

Designing Lot Release Specifications That Both Protect Patients and Enable Commercial Manufacturing

The XGene Cell Therapy Specification Justification Matrix is a structured, attribute-by-attribute specification design tool that builds the regulatory justification for every lot release criterion simultaneously with the acceptance criterion itself — so that the specification table submitted in the IND is already defended, not merely populated.

Step 1 — Attribute Classification and Regulatory Basis Assignment: For each proposed release attribute, assign the regulatory basis (ICH Q6B category, FDA guidance section, USP chapter) and document whether the criterion is safety-critical, identity-defining, or potency-relevant. This step forces the team to distinguish between attributes where CBER has published thresholds and those where the program must construct its own clinical/manufacturing justification from lot history data.

Step 2 — Acceptance Criterion Justification with Historical Data Mapping: For each numerical limit, map the criterion to the specific lots — preclinical, toxicology, Phase 1 — that establish the manufacturing range. Identify the lowest acceptable value observed across those lots and the clinical outcome data that supports it. Where data is insufficient in early phase, document the justification as “based on manufacturing capability” and define the data collection plan that will support tightening the criterion at Phase 2/3.

Step 3 — Rapid Testing Strategy Design for Autologous Products: For any attribute where the compendial method cannot return results within the product’s release window, identify the validated alternative method, document the validation approach, and assign the IND section where the strategy will be disclosed. This step prevents the single most common CBER sterility deficiency — a specification that cites USP <71> without acknowledging that the product will be infused before results are available.

Step 4 — Dose-Based Limit Conversion and Clinical Safety Rationale: Convert all safety specifications — endotoxin, residual reagents, residual nucleic acid for viral gene transfer products, vector copy number upper limits for CAR-T — to patient-dose-based limits, with a documented clinical safety rationale for each upper limit. For VCN specifications in lentiviral CAR-T products specifically, the upper limit must be supported by a genotoxicity risk argument, not merely a manufacturing capability argument.

The output of the XGene Cell Therapy Specification Justification Matrix is a specification justification dossier — organized by attribute, citing the regulatory basis, historical data anchor, rapid-testing rationale, and dose-based safety limit for each criterion — that can be submitted directly as a supporting document to the IND CMC section and used without revision as the basis for a pre-BLA specification discussion with CBER.

Cell therapy lot release specifications that lack quantitative acceptance criteria, dose-based safety limits, and a validated rapid-testing strategy do not simply create regulatory risk — they create the conditions under which a manufactured lot cannot be released, an autologous patient cannot be treated on schedule, and a pre-BLA meeting becomes a negotiation over data that should have been generated at Phase 1. The cost of a deficient specification architecture is not paid once at the IND; it compounds at every stage where the program lacks the historical data to justify the numerical criterion CBER is asking for. Programs that defer specification justification routinely encounter the same CBER comment at Phase 2 that they could have prevented with a defensible Phase 1 package — and at Phase 2, the lot history to support tightening the criterion is often still insufficient. A specification philosophy established at IND, with the XGene Cell Therapy Specification Justification Matrix as its operating architecture, is the instrument that prevents this compounding deficit.

For your cell therapy drug product lot release specification, can you identify today whether viability has a defined lower limit with documented justification, whether your sterility testing strategy includes a rapid method to support release timeline for autologous products, and whether your VCN specification for viral transduction products has an upper limit with a clinical safety rationale?